secwatch.observer — SEC 8-K summary
======================================

Issuer:     Indivior Pharmaceuticals, Inc. (INDV)
CIK:        0001625297
Form:       8-K
Filed at:   2026-03-17T23:59:59+00:00
Accession:  0001625297-26-000015
Event type: debt
Sentiment:  neutral
Materiality: 0.60
Item codes: 1.01, 1.02, 2.03, 3.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Indivior issues $500M 0.625% convertible notes due 2031; repays existing debt
-----------------------------------------------------------------------------

- $500M principal of 0.625% Convertible Senior Notes due March 15, 2031 issued; initial purchasers' option fully exercised for additional $50M.
- Initial conversion price of ~$41.66 per share (35% premium over March 12 close); max ~16.2M shares issuable upon conversion.
- Proceeds used to prepay all outstanding principal, interest, and fees under November 2024 Note Purchase Agreement; that agreement terminated.
- Notes redeemable at Indivior's option after March 20, 2029 if stock exceeds 130% of conversion price for 20 of 30 trading days.
- Notes are senior unsecured, structurally subordinated to subsidiary liabilities; interest payable semi-annually on March 15 and September 15.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1625297/000162529726000015/0001625297-26-000015-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1625297/000162529726000015/indv-20260317.htm
  HTML page:      https://secwatch.observer/filing/0001625297-26-000015

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer